Growing body of clinical and real-world evidence supports the role of Rezdiffra® (resmetirom) as the foundational therapy for patients with MASH ...

Rezdiffra (resmetirom) is a prescription drug used to treat certain types of nonalcoholic steatohepatitis (NASH). Rezdiffra can cause side effects that range from mild to serious, such as diarrhea and ...

Please provide your email address to receive an email when new articles are posted on . Experts recommend confirming MASH diagnosis by assessing steatosis via ultrasound or FibroScan. MRI-proton ...

Rezdiffra (resmetirom) is a brand-name drug prescribed for a type of liver disease called metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH) ...

Rezdiffra may affect the way other medicines work, and other medicines may affect how Rezdiffra works. Especially tell your healthcare provider if you take medicines that contain gemfibrozil to help ...

Rezdiffra (resmetirom) is a brand-name medicine that’s prescribed with diet and exercise to treat a liver condition called MASH (previously called NASH) in certain adults. More common mild side ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

Rezdiffra (resmetirom) is a brand-name oral tablet prescribed for nonalcoholic steatohepatitis (NASH) in certain situations. It is typically taken once per day. The dosage varies based on a person’s ...

The last time I spoke about Madrigal Pharmaceuticals (MDGL), it was with respect to a Seeking Alpha article entitled "Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long Term." ...

Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...

Credit: Madrigal Pharmaceuticals. Rezdiffra is supplied in 60mg-, 80mg-, and 100mg-strength tablets and is distributed through a limited specialty pharmacy network. Rezdiffra should be avoided in ...

The decades-long wait for an effective treatment for metabolic dysfunction-associated steatohepatitis (MASH) has ended, as the FDA has approved the first drug for the fatty liver disease. After a long ...